You are here

Adult Seizure Drug Ganaxolone Flops in Late-Stage trial

GABA modulator is equivalent to placebo

The investigational compound ganaxolone (Marinus Pharmaceuticals), a central nervous system–selective gamma-aminobutyric acid A (GABAA) modulator, has failed to demonstrate a statistically significant difference from placebo (the primary endpoint) in a pivotal phase 3 study of adults with drug-resistant focal-onset seizures. Marinus plans to discontinue its program in adult focal-onset seizures and focus its efforts on evaluating ganaxolone in status epilepticus and in pediatric orphan indications.

The pivotal double-blind, randomized, placebo-controlled study was conducted at 61 sites in the United States and Europe. A total of 359 patients were randomly assigned to receive treatment with ganaxolone 1,800 mg per day (n = 179) or placebo (n = 180). The patients’ mean age was 41 years, and 63% were female. Most of the patients (76%) were receiving two or more concomitant antiepileptic drugs, and 12% had been treated with a vagus nerve stimulator.

The study missed its primary endpoint of a percent change in the 28-day seizure frequency from baseline (P = 0.1537). The median percent reduction of focal-onset seizures in the ganaxolone group was 21.3% compared with 10.3% in the placebo group during the titration and 12-week treatment periods.

Serious adverse events were reported in 5.0% and 5.1% of the active-treatment and placebo groups, respectively. The most common adverse events reported in ganaxolone-treated patients compared with those given placebo included somnolence (23.5% vs. 4.5%, respectively), dizziness (19.6% vs. 4.5%), and fatigue (11.7% vs. 6.8%). Most of these adverse events were mild in severity. Forty-four patients (25%) in the ganaxolone group discontinued treatment compared with 26 patients (14%) in the placebo group. The most common reason for discontinuation was an adverse event.

Ganaxolone was being developed for adult and pediatric patients in both the acute and chronic-care settings. The compound acts on a synaptic and extrasynaptic GABAA target known for its antiseizure and antianxiety activity. Ganaxolone has been studied in more than 1,300 pediatric and adult subjects at therapeutically relevant dose levels for up to two years.

Source: Marinus Pharmaceuticals; June 13, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs